Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Non-Current Deffered Revenue (2023 - 2025)

Beta Bionics' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue rose 77.26% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, up 77.26%, while the annual FY2025 figure was $3.3 million, 77.26% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $3.3 million at Beta Bionics, up from $3.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $3.3 million in Q4 2025 and bottomed at $255000.0 in Q4 2023.
  • The 3-year median for Non-Current Deffered Revenue is $2.5 million (2025), against an average of $2.2 million.
  • The largest annual shift saw Non-Current Deffered Revenue surged 629.41% in 2024 before it soared 77.26% in 2025.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $255000.0 in 2023, then soared by 629.41% to $1.9 million in 2024, then soared by 77.26% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Non-Current Deffered Revenue are $3.3 million (Q4 2025), $3.0 million (Q3 2025), and $2.7 million (Q2 2025).